What do systematic reviews say?

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No evidence of a difference in reported adverse events across the three trials (nausea, fever, constipation, diarrhoea, headache, fatigue and others)
  3 studies
  GRADE not reported

Amifostine (intravenous) vs Amifostine (subcutaneous)

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  Increased hypotension with intravenous delivery (20% vs 8%; P = 0.007); skin rash (10% vs 22%; P = 0.012) and local pain at injection site (0% vs 8%; P = 0.001) worse with subcutaneous; inconclusive for…
  1 study
  GRADE not reported

Post‐treatment communication (text messaging) vs No communication (no text message)

The review found no eligible studies for this question.

• Non‐pharmacological interventions for alleviating pain during orthodontic treatment 2016 · Cochrane All outcomes
  Adverse effects: Not measured.
  Studies not reported
  No studies found

Low‐level laser therapy vs Placebo (or no irradiation)

The review found no eligible studies for this question.

• Non‐pharmacological interventions for alleviating pain during orthodontic treatment 2016 · Cochrane All outcomes
  Adverse effects: Not measured.
  Studies not reported
  No studies found

CBT vs No special instructions (control)

The review found no eligible studies for this question.

• Non‐pharmacological interventions for alleviating pain during orthodontic treatment 2016 · Cochrane All outcomes
  Adverse effects for CBT: Not measured.
  Studies not reported
  No studies found

Experimental chewing adjuncts (bite wafers or chewing gum) vs No chewing gum, placebo, or control (no adjunct)

The review found no eligible studies for this question.

• Non‐pharmacological interventions for alleviating pain during orthodontic treatment 2016 · Cochrane All outcomes
  Adverse effects: Not measured.
  Studies not reported
  No studies found

Brain wave music (BWM) vs No special instructions (control)

The review found no eligible studies for this question.

• Non‐pharmacological interventions for alleviating pain during orthodontic treatment 2016 · Cochrane All outcomes
  Adverse effects for BWM: Not measured.
  Studies not reported
  No studies found

Vibratory stimulation (vibratory adjuncts) vs No vibration or placebo vibration

The review found no eligible studies for this question.

• Non‐pharmacological interventions for alleviating pain during orthodontic treatment 2016 · Cochrane All outcomes
  Adverse effects: Not measured.
  Studies not reported
  No studies found

Amifostine vs no treatment/placebo

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  Alopecia, skin toxicity, hot flush, drowsiness, sneezing, hiccupping, dizziness and fatigue reported narratively or only for the amifostine group; insufficient evidence of a difference
  Studies not reported
  GRADE not reported

Pilocarpine vs no treatment/placebo

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No evidence of a difference for any other adverse event (nausea, vomiting, chilling, headache, lacrimation, dysphasia, weakness, nervousness, rhinitis, blurred vision, urinary frequency, dizziness, palpitation, skin…
  Studies not reported
  GRADE not reported

Summary of findings table ‐ Topical capsaicin vs placebo

• Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes

  4 weeks
  Three participants from the topical capsaicin group withdrew from the study by Winocur et al 2000 due to the severity of the burning sensation and redness.
  1 study · 30 participants
  GRADE not reported

Oral gabapentin vs placebo

• Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes

  12 weeks
  Four of the participants withdrew from the study by Kimos et al 2007 due to adverse effects, but neither the type of adverse effect nor the trial group was specified.
  1 study · 44 participants
  GRADE not reported

Oral glucosamine hydrochloride/chondroitin sulphate vs placebo

• Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes

  3 months
  Two allergic reactions and one severe abdominal pain led to three withdrawals from the intervention group in the study by Nguyen et al 2001.
  1 study · 45 participants
  GRADE not reported

Oral clonazepam (benzodiazepine) vs placebo

• Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes

  60 days
  One participant in the clonazepam group withdrew from the study by Harkins et al 1991 due to severe headache.
  1 study · 20 participants
  GRADE not reported